- Home
- PEN vs RDY Comparison
PEN vs RDY Comparison
Compare PEN & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- RDY
- Stock Information
- Founded
- PEN 2004
- RDY 1984
- Country
- PEN United States
- RDY India
- Employees
- PEN N/A
- RDY N/A
- Industry
- PEN Medical/Dental Instruments
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- RDY Health Care
- Exchange
- PEN Nasdaq
- RDY Nasdaq
- Market Cap
- PEN 10.9B
- RDY 11.6B
- IPO Year
- PEN 2015
- RDY N/A
- Fundamental
- Price
- PEN $289.53
- RDY $13.81
- Analyst Decision
- PEN Strong Buy
- RDY Strong Buy
- Analyst Count
- PEN 16
- RDY 1
- Target Price
- PEN $307.19
- RDY $16.90
- AVG Volume (30 Days)
- PEN 526.4K
- RDY 1.2M
- Earning Date
- PEN 11-05-2025
- RDY 10-24-2025
- Dividend Yield
- PEN N/A
- RDY 0.51%
- EPS Growth
- PEN 367.34
- RDY 9.95
- EPS
- PEN 4.14
- RDY 0.79
- Revenue
- PEN $1,333,798,000.00
- RDY $3,851,623,984.00
- Revenue This Year
- PEN $15.52
- RDY $6.29
- Revenue Next Year
- PEN $14.20
- RDY $2.61
- P/E Ratio
- PEN $69.71
- RDY $17.52
- Revenue Growth
- PEN 14.61
- RDY 14.10
- 52 Week Low
- PEN $221.26
- RDY $12.26
- 52 Week High
- PEN $310.00
- RDY $16.17
- Technical
- Relative Strength Index (RSI)
- PEN 68.64
- RDY 44.70
- Support Level
- PEN $276.01
- RDY $13.71
- Resistance Level
- PEN $293.18
- RDY $14.10
- Average True Range (ATR)
- PEN 8.67
- RDY 0.18
- MACD
- PEN 2.92
- RDY 0.04
- Stochastic Oscillator
- PEN 95.40
- RDY 53.32
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.